[Quality analysis for treatment of heart muscle diseases].
Distinct examinations and resulting therapies are depending on the cardiomyopathy phenotype and the severity of the myocardial compromise. Specific treatment modalities for distinct cardiomyopathies, demand detailed diagnostic procedures in addition to the routine diagnostic workup. Quality analyses for causal treatment strategies of different cardiomyopathies are missing. Most diagnostic procedures are unable to detect the relevant pathophysiological changes that generally occur at the cellular and molecular level of myocardial tissue or individual cells. Therefore, often only additional biopsy-based tissue analyses can provide the necessary basis for causal treatment options.
Schultheiss
H-P
HP
Medizinische Klinik II, Kardiology und Pneumonology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin. heinz-peter.schultheiss@charite.de
Lassner
D
D
Kühl
U
U
D001706:Biopsy; D006332:Cardiomegaly / Q000628:therapy; D009202:Cardiomyopathies / Q000145:classification / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002313:Cardiomyopathy, Restrictive / Q000145:classification / Q000235:genetics / Q000473:pathology / Q000628:therapy; D003937:Diagnosis, Differential; D004562:Electrocardiography / Q000379:methods; D006331:Heart Diseases / Q000628:therapy; D006801:Humans; D009154:Mutation; D009200:Myocardial Contraction; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D011785:Quality Assurance, Health Care